Merck's drug Pimicotinib for the treatment of tenosynovial giant cell tumor has received acceptance for its market authorization application

智通財經
2025.06.10 04:20
6 月 10 日，默克宣佈，中國國家藥品監督管理局藥品審評中心已正式受理其 1 類創新藥 Pimicotinib 的上市許可申請，用於需要系統性治療的腱鞘鉅細胞瘤成人患者。默克醫藥健康全球執行副總裁、中國及國際市場負責人周虹表示，公司正同步推進向美國 FDA 提交上市許可申請，並計劃在其他市場陸續申報。
Source: 智通財經 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.